Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis

NCT ID: NCT02242747

Last Updated: 2014-09-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-05-31
• Study Completion Date: 2014-08-31

Brief Summary

Background: 5% 5-fluorouracil cream (5-FU) is a well-established treatment for actinic keratosis (AK) and ingenol mebutate gel (IMB) is a new topical field therapy.

Objective: To compare tolerability and safety of IMB with 5-FU for the treatment of facial AKs.

Methods: Open-label, prospective, randomized, controlled clinical trial with 100 patients with AKs within 25-cm2 contiguous field on the face. IMB was applied daily for three consecutive days. 5-FU was applied twice a day for four weeks. Treatment effect was evaluated at baseline and on days 2, 3, 4, 8, 15, 22, 29, 36 and 43, considering ITT populations.

Conditions

Actinic Keratosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ingenol mebutate

Patients assigned to ingenol mebutate gel received an application a day for three consecutive days in a pre-determined area

Group Type: OTHER

ingenol mebutate

Intervention Type: DRUG

an application a day for three consecutive days in a pre-determined area

5% 5-FU

Patients assigned to 5% 5-FU received two applications a day for four weeks in a pre-determined area

Group Type: OTHER

5% 5-FU

Intervention Type: DRUG

two applications a day for four weeks in a pre-determined area

Interventions

ingenol mebutate

an application a day for three consecutive days in a pre-determined area

Intervention Type: DRUG

5% 5-FU

two applications a day for four weeks in a pre-determined area

Intervention Type: DRUG

Other Intervention Names

Picato; efurix; efudex

Eligibility Criteria

Inclusion Criteria

• age of at least 18 years
• the presence of four to eight clinically typical, visible, and discrete AKs within 25-cm2 contiguous field on the face (cheek or forehead region)
• Women with childbearing potential had to be using effective birth control and have a confirmed negative urine pregnancy test prior to trial treatment.

Exclusion Criteria

• target treatment area was within 5 cm of an incompletely healed wound or within 10 cm of a suspected basal-cell or squamous-cell carcinoma
• if they have received previous treatment with ingenol mebutate gel on the face or scalp (previous treatment on trunk or extremities was acceptable)
• the selected treatment area had hyperkeratotic lesions or cutaneous horns and recalcitrant disease (lesions that had not responded to cryotherapy on two previous occasions)
• history or evidence of skin conditions that would interfere with the evaluation of the trial medication (e.g., eczema, unstable psoriasis, xeroderma pigmentosum)
• anticipated need for hospitalization or outpatient surgery during the first 15 days after the first trial medication application
• known sensitivity or allergy to any of the ingredients of ingenol mebutate gel or 5-FU
• presence of sunburn within of the target treatment area; current enrolment or participation in any other interventional clinical trial within 30 days of entry into this trial
• women breastfeeding
• recent use of medications or other treatments that could interfere with evaluation of the target area, such as topical medications (e.g. steroids, keratolytics, immunomodulators), artificial tanners, immunomodulators, cytotoxic drugs or interferon /interferon inducers, phototherapy, systemic retinoids, biologic/monoclonal antibody drugs, or other therapies for AKs within eight weeks prior to the first visit of the trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

LEO Pharma

INDUSTRY

Sponsor Role: collaborator

University of Sao Paulo

OTHER

Sponsor Role: lead

Responsible Party

Luis Antonio Torezan

Associate Professor University of Sao Paulo

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Luis Antonio Torezan, PhD

Role: PRINCIPAL_INVESTIGATOR

Hospital das Clínicas of the University of São Paulo Medical School (HCFMUSP)

Locations

Hospital das Clínicas of the University of São Paulo Medical School (HCFMUSP)

São Paulo, São Paulo, Brazil

Countries

Brazil

References

Samorano LP, Torezan LA, Sanches JA. Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial. J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1822-7. doi: 10.1111/jdv.13063. Epub 2015 Feb 27.

Reference Type: DERIVED

PMID: 25727104 (View on PubMed)

Other Identifiers

11334

Identifier Type: -

Identifier Source: org_study_id